IMPEDIMED LIMITED — Interim / Quarterly Report 2015

Aug 25, 2015

Appendix 4E Preliminary final report Period ending 30 June 2015

ImpediMed Limited - Appendix 4E ABN 65 089 705 144 Preliminary final report 1 Current Financial Period Ended: 30 June 2015 Previous Corresponding Reporting Period: 30 June 2014

The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2015 ("2015 Financial Report") and any public announcements made by ImpediMed Limited and its controlled entities during the year in accordance with continuous disclosure obligations arising under the ASX Listing Rules.

==> picture [454 x 461] intentionally omitted <==

----- Start of picture text -----

2 Results for announcement to the market
Previous
Current reporting corresponding
period period
$000 $000
2.1 Revenue from ordinary activities $ (4,927) $ (3,578)
Increase (decrease) in revenue ($000): $ 1,349
Percentage increase (decrease): 38%
Note : Revenue related to goods and services increased for the year ended 30 June 2015 to $4.9
million (2014 $3.6 million), an increase of $1.3 million year over year. The change by operating
segment was an increase of $0.5 million in medical, and a $0.8 million increase in test &
measurement. The $0.5 million increase in the medical segment was due to a $0.1 million increase
in body composition and veterinary products, while total lymphoedema product revenue for the
Group increased by $0.4 million, or 28% year over year.
2.2 Profit/(loss) from ordinary activities after tax
attributable to members (14,797) (7,935)
Increase/(decrease) in profit from ordinary
activities after tax attributable to members ($000): $ (6,862)
Percentage increase/(decrease): -86%
Note : Refer to the Directors' Report for a more extensive analysis; however, in summary, in addition
to the increase in revenue above:
- salaries and benefits expense increased by $4.4 million
- research and development expenses increased by $0.6 million
- consultants and professional fees increased by $0.5 million
- advertising and promotion expense increased by $0.8 million
- travel expense increased by $0.5 million
2.3 Net profit/(loss) for the period attributable
to members (14,797) (7,935)
Increase/(decrease) in net profit for the period
attributable to members ($000): $ (6,862)
Percentage increase/(decrease): -86%
Note: Refer to 2.2 above and to the Directors' Report in the 2015 Financial Report.
3 Dividends
3.1 Dividends Nil
There were no dividends declared and paid during the reporting period on ordinary shares.
There were no dividends proposed and not yet recognised as a liability during the reporting period.
3.2 Dividend Record Date Not applicable
----- End of picture text -----

Appendix 4E Preliminary final report Period ending 30 June 2015

4 Financial Statements

4.1 Statement of comprehensive income

Refer to the Consolidated Statement of Comprehensive Income in the 2015 Financial Report.

4.2 Statement of financial position

Refer to the Consolidated Balance Sheet in the 2015 Financial Report.

4.3 Statement of cash flows

Refer to the Consolidated Cash Flow Statement in the 2015 Financial Report.

4.4 Statement of retained earnings

Refer to the Consolidated Statement of Changes in Equity in the 2015 Financial Report for movements in retained earnings.

• 5 Net tangible assets per security

					Previous
		Current reporting			corresponding
			period		period
5.1	Net tangible assets ($000)		32,429		11,567
	Issued share capital at reporting date ($000)		147,349		116,593
					Previous
		Current reporting			corresponding
			period		period
	Number of shares on issue at reporting date		293,287,840		238,672,802
	Net tangible assets per security	$	0.11	$	0.05
6	Earnings per security
					Previous
		Current reporting			corresponding
			period		period
6.1	Weighted average number of ordinary shares (excluding		268,288,850		195,605,935
	reserved shares) for basic earnings per share (EPS)
	Loss per share from continued operations
	Basic EPS	$	-	$	-
	Loss per share from profit attributable to ordinary shares
	Basic EPS	$	-	$	-
	Diluted earnings per share has been determined to be the same		as basic earnings per share as
	the actual calculation is anti-dilutive for both periods presented.
	Refer to Note 1 - Earnings per share in the Annual Financial Report for the year			ended 30 June
	2015 for additional information pertainingto EPS for the current reportingperiod.
7	Acquisitions and divestments
	There were no entities over which control has beengained or lost duringthe reporting period.
8	Foreign entities
	Not applicable.
9	Associates and joint ventures
	Not applicable.
10	Commentary on results for the financial year
	Refer to the Annual Financial Report for the year ended 30 June		2015.
11	Results of segments
	Refer to Note 3 - Segment reporting in the Annual Financial Report for the year			ended 30 June
	2015 for additional information pertaining to segment results for the current reporting period.
12	Audited Report
	The report is based on audited accounts which are not subject to dispute, modification, or qualification.